Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMO7MTX)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
N-n-Propylnorapomorphine; 4H-Dibenzo(de,g)quinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-propyl-; 57559-68-9; Propyl-norapomorphine; Propylnorapomorphine; 6-Propyl-5,6,6a,7-tetrahydro-4H-dibenzo(de,g)quinoline-10,11-diol; (+-)-N-n-Propylnorapomorphine; 10,11-Dihydroxy-6-propylnoraporphine; AC1L1IVU; GTPL934; SCHEMBL249729; R(-)-PROPYLNORAPOMORPHINE; 6-Propyl- 5,6,6a,7-tetrahydro-4H-dibenzo(de,g)quinoline-10,11-diol
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||
|
||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Hematopoietic system
Normal
Kidney
Normal (Immortalized)
Liver
Hepatoblastoma
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
